首頁 > 市場調查報告書 > 製藥

全球靜脈鐵劑藥物市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1342728

全球靜脈鐵劑藥物市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Intravenous Iron Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 127 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球靜脈鐵劑市場需求預計將從 2022 年的 58.3 億美元增至 2030 年的近 413.3 億美元，2023-2030 年研究期間年複合成長率為 24.31%。

靜脈補鐵藥物是通過將一根細管插入手臂靜脈並注射含鐵的液體溶液來將鐵輸送到體內的過程。這些藥物優於口服補充劑，因為它們可以更快更快地提高鐵和血紅蛋白水平。這些藥物的其他好處包括增加能量水平和更輕鬆的呼吸。

市場動態

慢性腎病和貧血的發病率不斷上升可能有助於該市場的成長。由於從口服含鐵藥物向靜脈注射含鐵藥物的轉變，市場需求也在上升。此外，全球炎症性腸病（IBD）和癌症病例的增加增加了對靜脈鐵劑藥物的需求，預計這將推動市場成長。由於研發活動的增加，對靜脈鐵劑藥物的需求不斷成長，推動了全球靜脈鐵劑藥物市場的成長。此外，人們對貧血診斷和治療的認知不斷提高，預計將在預測期內擴大市場成長。然而，高昂的治療成本可能會限制該市場的成長。

該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球靜脈鐵劑藥物市場的各個細分市場進行了包容性評估。靜脈鐵劑藥物行業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲靜脈鐵藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。靜脈鐵劑藥物市場的主要參與者包括Vifor Pharma Management Ltd.、AMAG Pharmaceuticals、Daiichi Sankyo Company, Ltd.（American Regent. Inc.）、Sanofi SA、Pharmacosmos A/S、Shield Therapeutics Plc、AbbVie Inc.（Allergan ）有限公司）。本節包含競爭格局的整體視圖，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概述、歷史和預測銷售分析
- 北美按細分市場銷售分析
- 北美按國家/地區銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概述、歷史和預測銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家/地區銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概述、歷史和預測銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概述、歷史和預測銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家/地區銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概述、歷史和預測銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：靜脈鐵劑藥物公司的競爭格局

靜脈鐵劑藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市場佔有率分析
市場集中度
Vifor Pharma Management Ltd.

公司簡介
公司收入
產品
最近的發展

AMAG Pharmaceuticals

公司簡介
公司收入
產品
最近的發展

Daiichi Sankyo Company Ltd. (American Regent. Inc.)

公司簡介
公司收入
產品
最近的發展

Sanofi SA

公司簡介
公司收入
產品
最近的發展

Pharmacosmos A/S

公司簡介
公司收入
產品
最近的發展

Shield Therapeutics Plc

公司簡介
公司收入
產品
最近的發展

AbbVie Inc. (Allergan Plc)

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR11219778

The global demand for Intravenous Iron Drugs Market is presumed to reach the market size of nearly USD 41.33 BN by 2030 from USD 5.83 BN in 2022 with a CAGR of 24.31% under the study period 2023 - 2030.

Intravenous iron drug supplementation is the process of delivering iron to the body by inserting a tiny tube into the vein of the arm and administering a liquid solution containing iron. These drugs are superior to oral supplements as they increase the iron and Hb levels higher and faster. Other benefits of these drugs include increased energy levels and easier breathing.

MARKET DYNAMICS

The growing incidences of chronic kidney diseases & anaemia may contribute to the growth of this market. The demand for the market is also rising due to the shifting trend from oral ferrous drugs to intravenous ferrous drugs. Moreover, increasing cases of inflammatory bowel disease (IBD) and cancer worldwide have increased demand for intravenous iron drugs, which is expected to drive market growth. The growing demand for intravenous iron drugs due to the rising research & development activities is fueling the global intravenous iron drugs market growth. Also, the increasing awareness of the diagnosis and treatment of anaemia is expected to scale up the market growth during the forecast period. However, the high cost of treatment may limit the growth of this market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of intravenous iron drugs. The growth and trends of intravenous iron drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the intravenous iron drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others

By Application

Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Intravenous Iron Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the intravenous iron drugs market include Vifor Pharma Management Ltd., AMAG Pharmaceuticals, Daiichi Sankyo Company, Ltd. (American Regent. Inc.), Sanofi S.A., Pharmacosmos A/S, Shield Therapeutics Plc, AbbVie Inc. (Allergan Plc). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . INTRAVENOUS IRON DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL INTRAVENOUS IRON DRUGS MARKET ANALYSIS BY PRODUCT

6.1 Overview by Product
6.2 Historical and Forecast Data
6.3 Analysis by Product
6.4 Iron Dextran Historic and Forecast Sales by Regions
6.5 Iron Sucrose Historic and Forecast Sales by Regions
6.6 Ferric Carboxymaltose Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL INTRAVENOUS IRON DRUGS MARKET ANALYSIS BY APPLICATION

7.1 Overview by Application
7.2 Historical and Forecast Data
7.3 Analysis by Application
7.4 Chronic Kidney Disease Historic and Forecast Sales by Regions
7.5 Inflammatory Bowel Disease Historic and Forecast Sales by Regions
7.6 Cancer Historic and Forecast Sales by Regions
7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL INTRAVENOUS IRON DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE INTRAVENOUS IRON DRUGS COMPANIES

9.1. Intravenous Iron Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF INTRAVENOUS IRON DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Vifor Pharma Management Ltd.
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. AMAG Pharmaceuticals
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Daiichi Sankyo Company Ltd. (American Regent. Inc.)
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Sanofi S.A.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Pharmacosmos A/S
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Shield Therapeutics Plc
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. AbbVie Inc. (Allergan Plc)
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments